50 employees
KeyNeurotek is focused on developing small molecule drugs for the treatment of neuronal and autoimmune diseases.
2012
$11M
from 3 investors over 3 rounds
KeyNeurotek Pharmaceuticals raised $11M on April 7, 2009
Investors: IBG Beteiligungsgesellschaft, DVC Deutsche Venture Capital and KfW